Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Scientific meetings with external peer review

2023

M. W. Lwin, C.-Y. Cheng, S. Calderazzo, C. Schramm, M. Schlander:
Would initiating colorectal cancer screening from Age 45 be cost-effective in Germany? An individual-level simulation analysis.
Poster presentation at ISPOR Europe 2023.
Copenhagen, Denmark. November 12-15, 2023.

M. Muchadeyi, S. Hao, K. Hernandez-Villafuerte, S. Khan, P. Albers, M. Schlander, M. Clements:
Prostate cancer screening in Germany: A microsimulation based cost-effectiveness analysis.
Poster presentation at ISPOR Europe 2023.
Copenhagen, Denmark. November 12-15, 2023.

M. Muchadeyi, K. Hernandez-Villafuerte, G. Di Tanna, R. Eckford, Y. Feng, M. Meregaglia, T. Peasgood, S. Petrou, J. Ubels, M. Schlander:
Development of a quality appraisal tool for systematic literature reviews of studies eliciting health state utility values (HSUVs): A modified-Delphi consensus approach.
Poster presentation at ISPOR Europe 2023.
Copenhagen, Denmark. November 12-15, 2023.

P. D. Pham, J. Ubels, M. Schlander:
Measuring the socioeconomic impact of cancer: A systematic review and standardized assessment of patient-reported outcome (PRO) instruments.
Poster presentation at ISPOR Europe 2023.
Copenhagen, Denmark. November 12-15, 2023.

M. Schlander, D. Hernandez, O. Schwarz, R. Schaefer:
What is a year of life worth? Empirical findings from worldwide economic studies on the value of a statistical life.
Poster presentation at ISPOR Europe 2023.
Copenhagen, Denmark. November 12-15, 2023.

2022

A. Gaisser, R. D. Eckford, V. Arndt, M. Baumann, E. Kludt, K. Mehlis, J. Ubels, E. Winkler, S. Weg-Remers, M. Schlander:
Auswirkungen der corona-pandomie aus perspective von krebsbetroffenen: Ergebnisse einer querschnittsstudie.
Oral presentation at the 35th German Cancer Congress (DKK).
Berlin, Germany. November 13-16, 2022.

A. Molnar, M. Störzel, M. Muchadeyi, R. Baird, I. Imaz-Igelsia, B. Nagy, J. M. Postma, G. de Pouvourville, V. Retel, M. Schlander:
Health economic evaluations alongside new clinical trial designs – Results of an international expert panel workshop.
Poster presentation at ISPOR Europe 2022.
Vienna, Austria. November 6–9, 2022.
Value in Health, 2022: 25(12, Supplement) S354.
DOI: 10.1016/j.jval.2022.09.1755.

M. Muchadeyi, K. Hernandez-Villafuerte, M. Schlander:
The nature of quality appraisal in systematic literature reviews of health state utility values (HSUVS). A rapid evidence review.
Poster presentation at ISPOR Europe 2022.
Vienna, Austria. November 6–9, 2022.
Value in Health, 2022: 25(12, Supplement) S429.
DOI: 10.1016/j.jval.2022.09.2135.

P. D. Pham, J. Ubels, K. Hernandez-Villafuerte, R. Eckford, M. Schlander:
Developing a conceptual framework for socioeconomic impact research in European cancer patients: A best-fit framework synthesis.
Poster presentation at ISPOR Europe 2022.
Vienna, Austria. November 6–9, 2022.
Value in Health, 2022: 25(12, Supplement) S430.
DOI: 10.1016/j.jval.2022.09.2141.

C. Quirland, F. Maza, J. Fuentes, R. Eckford, J. Ubels, O. Seoane, D. Hernandez, K. Hernandez-Villafuerte, P.D. Pham, V. Retel, M. Schlander:
Costing for Socioeconomic Impact Analysis: Implications of Adopting a Patient's Perspective.
Poster presentation at ISPOR Europe 2022.
Vienna, Austria. November 6–9, 2022.
Value in Health, 2022: 25(12, Supplement) S67.
DOI: 10.1016/j.jval.2022.09.326.

M. Schlander, J. Ubels, C. Quirland, V. Retel:
Towards a broader patients' perspective: The theory and practice of socioeconomic impact research.
Concurrent Breakout Session 4 at ISPOR Europe 2022.
Vienna, Austria. November 6–9, 2022.

J. Schneider, D. Hernandez, CAESAR study group, M. Schlander, V. Arndt:
To what extent are long-term breast cancer survivors subjected to financial burden in Germany? Results from a patient survey-based study.
Poster presentation at ISPOR Europe 2022.
Vienna, Austria. November 6–9, 2022.
Value in Health, 2022: 25(12, Supplement) S397.
DOI: 10.1016/j.jval.2022.09.1973.

M. Störzel, A. Molnar, M. Schlander:
Challenges of health economic evaluations alongside innovative clinical trial designs in precision oncology – Results of a literature review.
Poster presentation at ISPOR Europe 2022.
Vienna, Austria. November 6–9, 2022.
Value in Health, 2022: 25(12, Supplement) S154.
DOI: 10.1016/j.jval.2022.09.742.

R. Eckford, A. Gaisser, E. Kludt, S. Weg-Remers, M. Schlander:
Financial impact on cancer patients in Germany during the COVID-19 pandemic.
Oral presentation at World Cancer Congress (WCC) 2022. 
Geneva, Switzerland. October 18–20, 2022.

R. Schaefer, D. Hernandez, M. Schlander:
Cancer-related HTAs in England and Germany: A comparison of outcomes and evaluation criteria.
Oral presentation at World Cancer Congress (WCC) 2022.
Geneva, Switzerland. October 18–20, 2022.

J. Ubels:
Adaptation and measurement invariance: evidence for the WeRFree instrument.
Presentation at HDCA conference.
Antwerp, Begium. September 19-22, 2022.

R. Eckford, A. Gaisser, E. Kludt, S. Weg-Remers, M. Schlander:
Financial concerns of cancer patients in Germany during the COVID-19 pandemic: risk factors and impact on psychological distress.
Oral Presentation at European Conference on Health Economics (EUHEA).
Oslo, Norway. Jul. 5-8, 2022. 

K. Hernandez-Villafuerte, R. Eckford, M. Schlander:
The Socioeconomic Impact of Cancer on Patients and their Families: Making Sense of the European Published Evidence.
Oral Presentation at European Conference on Health Economics (EUHEA).
Oslo, Norway. Jul. 5-8, 2022.

P. D. Pham:
Cost-utility analysis comparing mastectomy and lumpectomy in early stage breast cancer surgeries in Sweden – a life-time approach using Markov modelling.
Presentation (online) at ISPOR.
Washington, DC, USA. May 15-18, 2022.
Value in Health, 2022: 25 (7, Supplement) S301.
DOI: 10.1016/j.jval.2022.04.082.

A. Gaisser, R. Eckford, E. Kludt, M. Baumann, S. Weg-Remers, M. Schlander:
Auswirkungen der Corona-Pandemie für Krebsbetroffene und ihre Versorgung: Ergebnisse einer Befragungsstudie.
Oral presentation (online) at EbM-Kongress,
Online-Pre-Conference. March 18, 2022.

2021

A. Gaisser, R. Eckford, E. Kludt, M. Baumann, S. Weg-Remers, M. Schlander:
Impact of the corona pandemic on cancer patients: Results from a German cross-sectional pilot study.
Poster presentation (online) at 20. Deutscher Kongress für Versorgungsforschung.
Virtual. October 6-8, 2021.

R. Eckford, A. Gaisser, V. Arndt, M. Baumann, E. Kludt, K. Mehlis, J. Ubels, E. C. Winkler, S. Weg-Remers, M. Schlander:
Online Survey of cancer patients on changes in care and on psycho-social burden during the pandemic.
Presentation at Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie.
Berlin, Germany (live and virtual). October 1-4, 2021.

J. Ubels, K. Hernandez-Villafuerte, M. Schlander:
Burdens and Capabilities: "Option Freedom" as a Health-Related Outcome Measure.
Presentation at iHEA 14th World Congress on Health Economics.
Virtual. July 12-15, 2021.

K. Hernandez-Villafuerte, R. Eckford, A. Spier, M. Schlander:
How to Describe the Socioeconomic Impact of Cancer on Patients and their Families: An Evaluation of Terminology by Global Regions and Healthcare Systems.
Presentation at iHEA 14th World Congress on Health Economics.
Virtual. July 12-15, 2021.

2020

C.-Y. Cheng, S. Calderazzo, C. Schramm, M. Schlander:
Modeling the duration of protective effects and resource use of colonoscopy screening by a discrete event simulation model calibrated with German screening registry data.
Poster presentation at ISPOR Europe 2020.
Virtual. November 16-19, 2020.
Value in Health, 2020: 23(Supplement 2) S456-S457.
DOI: 10.1016/j.jval.2020.08.328.

R. Eckford, K. Hernandez-Villafuerte, A. Spier, L. Hirschberg, M. Schlander:
A systematic review of the socioeconomic impact of cancer on patients and families: Are differences among countries being effectively captured and addressed?
Poster presentation at ISPOR Europe 2020.
Virtual. November 16-19, 2020.
Value in Health, 2020: 23(Supplement 2) S478.
DOI: 10.1016/j.jval.2020.08.453.

A. Molnar, T.J. Brinker, A. Hekler, K.V. Hernandez-Villafuerte, M. Schlander:
Direct costs related to medical management of malignant cutaneous melanoma through the patient pathway.
Poster presentation at ISPOR Europe 2020.
Virtual. November 16-19, 2020.
Value in Health, 2020 23(Supplement 2) S460.
DOI: 10.1016/j.jval.2020.08.348.

J. Richardson, M. J. Postma, S. Holm, M. Schlander:
Social cost value analysis: do we need an alternative health economic evaluation paradigm?
Conference Proceedings at ISPOR Europe 2020.
Virtual November 16-19, 2020.

R. Schäfer, D. Hernandez, M. Schlander:
The role of the budget impact: A multivariate analysis of health technology assessment (HTA) outcomes by GBA/IQWiG in Germany and NICE in England.
Poster presentation at ISPOR Europe 2020.
Virtual. November 16-19, 2020.
Value in Health, 2020: 23(Supplement 2) S530.
DOI: 10.1016/j.jval.2020.08.753.

M. SchlanderK. Hernandez-VillafuerteC.-Y. Cheng, J. Mestre-Ferrandiz, M. Baumann:
How much does it cost to research & develop a new medicine? A systematic review and evaluation of 40 years of literature.
Oral presentation at ISPOR Europe 2020.
Virtual. November 16-19, 2020.
Value in Health, 2020: 23(Supplement 2) S756.
DOI: 10.1016/j.jval.2020.08.2074.

M. Schlander, T. Ran, P. Schmidt, S.B. Eichmüller:
The acquisition cost and efficiency of CAR T cell therapies: can they be improved by decentralized manufacturing?
Poster presentation at ISPOR Europe 2020.
Virtual. November 16-19, 2020.
Value in Health, 2020: 23(S2) S460.
DOI: 10.1016/j.jval.2020.08.346.

A. Molnar, T.J. Brinker, T.B. Jutzi, K. Hernandez-Villafuerte, M. Schlander:
Direct and indirect cost of malignant cutaneous melanoma in European countries – Results of a literature review.
Abstract video presentation at the Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology.
Basel, Switzerland. October 9-11, 2020.

C.-Y. Cheng, S. Calderazzo, C. Schramm, M. Schlander:
Modeling the long-term effectiveness of colonoscopy screening by a discrete event simulation model calibrated with German screening registry data.
Poster presentation at the ESMO Congress 2020.
Virtual. September 19-21, 2020.
Annals of Oncology, 2020: 31(Supplement 4) S457-458.
DOI: 10.1016/j.annonc.2020.08.625.

D. Hernandez, M. Schlander:
Income loss after a cancer diagnosis from the patient perspective: an analysis based upon the German socio-economic panel (SOEP) survey.
Poster presentation at the ESMO Congress 2020.
Virtual. September 19-21, 2020.
Annals of Oncology, 2020: 31(Supplement 4) S962.
DOI: 10.1016/j.annonc.2020.08.1900.

K. Hernandez-Villafuerte, M. Schlander, C.-Y. Cheng, J. Mestre-Ferrandiz, M. Baumann:
How much does it cost to research and develop a new medicine? A systematic review and evaluation of 40 years of literature.
Poster presentation at the ESMO Congress 2020.
Virtual. September 19-21, 2020.
Annals of Oncology, 2020: 31(Supplement 4) S962.
DOI: 10.1016/j.annonc.2020.08.1898.

R. Schaefer, D. Hernández, M. Schlander:
Health technology assessment (HTA) in England, France and Germany: What do we know about variations in cancer-related HTA outcomes?
Poster presentation at the ESMO Congress 2020.
Virtual. September 19-21, 2020.
Annals of Oncology, 2020: 31(Supplement 4) S1197.
DOI: 10.1016/j.annonc.2020.08.2305.

M. Schlander, T. Ran, P. Schmict, S.B. Eichmüller:
Can we reduce the acquisition cost of CAR T cell therapies?
Poster presentation at the ESMO Congress 2020.
Virtual. September 19-21, 2020.
Annals of Oncology, 2020: 31(Supplement 4) S966.
DOI: 10.1016/j.annonc.2020.08.1912.

S.A. Khan, K. Hernandez-Villafuerte, M.T. Muchadeyi, M. Schlander:
Cost-effectiveness of risk-based breast cancer screening: a review of input parameters and optimal sreening strategies.
Poster presentation to the 2nd International DKFZ Conference on Cancer Prevention.
Virtual Meeting. September 17-18, 2020.

M. Thong, D. Doege, L. Weißer, L. Koch-Gallenkamp, H. Bertram, A. Eberle, B. Holleczek, A. Waldmann, S.R. Zeissig, R. Pritzkuleit, M. Schlander, H. Brenner, V. Arndt:
Health and life insurance-related problems in long-term cancer survivors in Germany: A population-based study.
Poster presentation to the 2nd International DKFZ Conference on Cancer Prevention.
Virtual Meeting. September 17-18, 2020.

R. Eckford, K. Hernandez-Villafuerte, L. Hirschberg, M. Schlander:
The social and socioeconomic impact of cancer on patients and their families: A systematic review.
Poster presentation to Virtual ISPOR.
Online. May 18-20, 2020.
Value in Health, 2020: 23(Supplement 1) S78.
DOI: https://doi.org/10.1016/j.jval.2020.04.1770.

D. Hernandez, M. Schlander:
Income loss after a cancer diagnosis in Germany: an analysis based upon the socio-economic panel survey.
Poster presentation to Virtual ISPOR.
Online. May 18-20, 2020.
Value in Health, 2020: 23(Supplement 1) S76.
DOI: 10.1016/j.jval.2020.04.1760.

R. Schäfer, D. Hernandez, M. Schlander:
Advancing evidence to action: A comparison of health technology assessment (HTA) outcomes in England, France and Germany.
Poster presentation to Virtual ISPOR, online Research Poster Session. May 18-20, 2020.
Value in Health, 2020: 23(S1) S70.
DOI: 10.1016/j.jval.2020.04.1736.

2019

R. Schaefer, D. Hernandez, M. Schlander:
Cancer-related HTA outcomes by European HTA agencies: a comparative analysis of G-BA, HAD and NICE.
Poster presentation at ISPOR 2019.
Copenhagen, Denmark. November 4, 2019.
Value in Health, 2019: 22(S3) S795-796.
DOI: 10.1016/j.jval.2019.09.2107

J. Ubels, M. Schlander, K. Hernandez Villafuerte:
The dynamics between capability and wellbeing.
Oral Presentation at the Conference Defining the Value of Medical Interventions-Normative and Empirical Challenges.
Fürth, Germany. September 16-20, 2019.

M. Schlander:
Social Cost Value Analysis for HTA
Oral Presentation at the Health Technology Assessment international (HTAi) Conference.
Panel Session: PN35 - HTA, Social Preferences Measurement, And (Ultra) Rare Disorders: Social Cost Value Analysis For HTA.
Cologne, Germany. June 15-19, 2019.

C.-Y. Cheng, T. Ran, M. Schlander:
Are the colorectal cancer screening methods used in Germany cost-effective? A systematic review of European studies.
Poster presentation at 1st German Cancer Research Congress 2019 (DKFK).
Heidelberg, Germany. February 4-5, 2019.
Congress Program Booklet, Heidelberg, Germany. February 2019: P005, p. 15.

M. Schlander, K. Hernandez Villafuerte, C. Thielscher:
The economic burden of cancer in Germany.
Poster presentation at 1st German Cancer Research Congress 2019 (DKFK).
Heidelberg, Germany. February 4-5, 2019.
Congress Program Booklet, Heidelberg, Germany. February 2019: P103, p. 29.

M. Schlander, D. Hernandez, J. Richardson, O. Schwarz, C. Thielscher:
Measuring health related quality of life for economic analysis and Health Technology Assessment (HTA): why should we exercise caution when using generic Multi-Attribute Utility (MAU) measurement instruments.
Poster presentation at 1st German Cancer Research Congress 2019 (DKFK).
Heidelberg, Germany. February 4-5, 2019.
Congress Program Booklet, Heidelberg, Germany. February 2019: P102, p. 29.

J. Mader, K. Hernandez Villafuerte:
Inequalities in cancer incidence among German districts: A spatial analysis exploring the role of behavioral and socioeconomic factors.
Poster presentation at 1st German Cancer Research Congress 2019 (DKFK).
Heidelberg, Germany. February 4-5, 2019.
Congress Program Booklet, Heidelberg, February 2019: P024, p. 18.

2018

M. Schlander, H. Telser, B. Fischer, T. von Rechenberg, R. Schäfer:
Should rarity matter? Results of a social willingness-to-pay study using the discrete choice experiment (DCE) method in Switzerland.
Poster Presentation at ISPOR 21st Annual European Congress 2018.
Barcelona, Spain. November 10–14, 2018.

C.-Y. Cheng, T. Ran, M. Schlander:
A systematic review update on cost-effectiveness of colorectal cancer screening: Identification of an optimal strategy in Europe.
Poster presentation at the National Cancer Research Institute (NCRI) Cancer Conference 2018.
Glasgow, Scotland. November 4-6, 2018.
British Journal of Cancer, 2018:119 (S1) 7.
DOI: 10.1038/s41416-018-0299-z

M. Schlander:
Kostenintelligenz im Gesundheitswesen: massgeschneiderte Erstattung für massgeschneiderte Therapien ["Cost intelligence in health care: tailor-made reimbursement for targeted therapies"].
Invited presentation at 7th Annual Meeting of House of Pharma & Healthcare.
Frankfurt a.M., Germany. September 10-11, 2018.

M. Schlander, D. Hernandez, R. Schäfer, O. Schwarz:
What are the drivers of the value of a statistical life year? An analysis of empirical economic studies from 1995 to 2015.
Oral Presentation at 12th European Conference on Health Economics (EuHEA).
Maastricht, Netherlands. July 14, 2018.

M. Schlander, H. Telser, B. Fischer, T. von Rechenberg, R. Schäfer:
Attributes of health interventions that drive social willingness-to-pay: Evidence from a discrete choice experiment.
Oral presentation at 12th European Conference on Health Economics (EuHEA).
Maastricht, Netherlands July 13, 2018.

J. Mestre-Ferrandiz, P. Anderson, T. Davis, J. Espin, S. Flostrand, B. Godman, A. Hutchings, C. Jommi, J. Mestre-Ferrandiz, A. Parnaby, M. Schlander:
Forecasting pharmaceutical expenditure in Europe: Adjusting for the impact of rebates and discounts.
Poster presentation at 12th European Conference on Health Economics (EuHEA)
Maastricht, Netherlands. July 12, 2018.

B. Fischer, R. Schäfer, M. Schlander, H. Telser, T. von Rechenberg:
Hypothetical bias and the role of information in discrete choice experiments.
Poster presentation at 12th European Conference on Health Economics (EuHEA).
Maastricht, Netherlands. July 12, 2018.

K. Hernandez-Villafuerte, B. Zamora, Y. Feng, D. Parkin, N. Devlin, A. Towse:
Issues on the estimation of the opportunity cost threshold value.
Poster presentation at the XXXVIII Spanish Health Economics Association Conference.
Las Palmas de Gran Canaria, Spain. June 20-22, 2018.

K. Hernandez-Villafuerte, J. Ubels, D. Hernandez, M. Schlander:
Efficacy of the multi-attribute utility instruments to reflect quality of life of cancer patients.
Poster presentation at Health Technology Assessment international (HTAi) Conference.
Vancouver, Canada. June 1-5, 2018.
International Journal of Technology Assessment in Health Care, 2018: 34(S1) 103.
DOI: 10.1017/S0266462318002428

K. Hernandez-Villafuerte, B. Zamora, Y. Feng, D. Parkin, N. Devlin, A. Towse:
Issues on the estimation of the opportunity cost threshold value.
Poster presentation at Health Technology Assessment international (HTAi) Conference.
Vancouver, Canada. June 1-5, 2018.
International Journal of Technology Assessment in Health Care, 2018: 34(S1) 115-116.
DOI: 10.1017/S0266462318002635

S. Bakshi, O. Sola-Morales, H. Telser, M. Schlander, D. Moro:
Social preferences in HTA: A discrete choice experiment (DCE) pilot analysis in CLN2 disease.
Poster presentation at Health Technology Assessment international (HTAi) Conference.
Vancouver, Canada. June 1-5, 2018.
International Journal of Technology Assessment in Health Care, 2018: 34(S1) 146-147.
DOI: 10.1017/S0266462318003148

M. Schlander, O. Schwarz, D. Hernandez, R. Schäfer:
The search for a cost effectiveness standard: 1-3 times GDP/Capita?
Poster presentation at Health Technology Assessment international (HTAi) Conference.
Vancouver, Canada. June 1-5, 2018.

M. Schlander, H. Telser, B. Fischer, T. von Rechenberg, R. Schäfer, and the ESPM Project Group:
Social preferences for health care interventions: The SoPHI ("Social Preferences for Health Care Interventions") study.
Poster presentation at Health Technology Assessment international (HTAi) Conference.
Vancouver, Canada. June 4, 2018.

M. Schlander, R. Gatermann:
Economical perspectives in rare diseases.
Conference Theme 5 for European Conference on Rare Diseases & Orphan Products (ECRD).
Vienna, Austria. May 10-12, 2018.
[M. Schlander and R. Gatermann were also serving as a members of the scientific program committee for the conference]

M. Schlander, M. Toumi, J. Richardson, S. Upadhyaya:
A paradigm shift in value frameworks for access?
Invited Symposium presented at European Conference on Rare Diseases & Orphan Products (ECRD).
Vienna, Austria. May 10-12, 2018.

M. Wagner, D. Samaha, R. Casciano, M. Brougham, C. Petrie, P. Abrishami, B. Avouac, P. Kind, L. Mantovani, A. Sarria Santamera, M. Schlander, M. Tringali:
Features of accountable and reasonable processes for coverage decision-making.
Presentation at HTAI 2018.
Vancouver, Canada. June 4, 2018.

M. Schlander:
Economical perspectives in rare diseases: "A paradigm shift in value frameworks for access".
Invited presentation at European Conference on Rare Diseases & Orphan Products (ECRD).
Vienna, Austria. May 10-12, 2018.

M. Schlander, H. Telser, B. Fischer, T. von Rechenberg, R. Schaefer:
Drivers of social value exceed length and quality of life: Evidence from Switzerland.
Poster presentation at ISPOR 23rd Annual International Meeting 2018, session on "Health Care Use & Policy Studies".
Baltimore, USA. May 22, 2018.
Value in Health, 2018: 21(S1) S115.
DOI: 10.1016/j.jval.2018.04.783

M. Schlander, O. Schwarz, D. Hernandez, R. Schaefer:
New estimates of the willingness-to-pay for a statistical life year: A systematic review of the empirical economic literature.
Poster presentation at ISPOR 23rd Annual International Meeting 2018, session on "Health care use & policy studies".
Baltimore, USA. May 22, 2018.
Value in Health, 2018: 21(S1) S111.
DOI: 10.1016/j.jval.2018.04.755

M. Wagner, D. Samaha, R. Casciano, M. Brougham, C. Petrie, P. Abrishami, B. Avouac, P. Kind, L. Mantovani, A. Sarría-Santamera, M. Schlander, M. Tringali:
Accountable and reasonable processes for coverage decision-making for rare disease and regenerative therapies—Which criteria should be considered and why?
Poster presentation at ISPOR 23rd Annual International Meeting 2018.
Baltimore, USA. May 21, 2018.
Value in Health, 2018: 21(S1) S52.
DOI: 10.1016/j.jval.2018.04.437

2017

J.J. Caro, A. McGuire, J. Brazier, M. Schlander:
Determining value in health technology assessment consistent with societal aims: Pursue new options?
Break-Out Session presented at ISPOR 20th Annual European Congress 2017.
Glasgow, UK. November 7, 2017.

J. Espin, M. Schlander, C. Jommi, B. Godman, P. Anderson, J. Mestre-Ferrandiz, A. Hutchings, S.Flostrand, A. Parnaby:
Forecasting pharmaceutical expenditure in Europe: Adjusting from the impact of rebates and discounts
Poster presentation at ISPOR 20th Annual European Congress 2017, session on "Health Care Use & Policy Studies".
Glasgow, UK. November 4-8, 2017.
Value in Health, 2017: 20(9) A664.
DOI: 10.1016/j.jval.2017.08.1603

R. Schaefer, O. Schwarz, M. Schlander:
"Appraising the appraisers": Do national Health Technology Assessment agencies (NICE, GBA/IQWIG) follow their official evaluation criteria?
Poster presentation at ISPOR 20th Annual European Congress, session on "Health Technology Assessment Studies".
Glasgow, UK. November 4-8, 2017.
Value in Health, 2017: 20(9) A410.
DOI: 10.1016/j.jval.2017.08.073

M. Schlander, R. Schaefer, O. Schwarz:
Empirical studies on the economic value of a statistical live year (VSLY) in Europe: What do they tell us?
Poster presentation at ISPOR 20th Annual European Congress 2017, session on "Health Care Use & Policy Studies".
Glasgow, UK. November 4-8, 2017.
Value in Health, 2017: 20(9) A666.
DOI: 10.1016/j.jval.2017.08.1618

M. Schlander:
From CUA to MCDA and SCVA.
Invited presentation at SPOR 20th Annual European Congress 2017.
Glasgow, UK. November 7, 2017.

I. Wiest, K. Obermann, C. Thielscher:
Drug cost containment and negotiation power.
Poster presentation at ISPOR 20th Annual European Congress.
Glasgow, UK. November 4-8, 2017.
Value in Health, 2017: 20(9) A676-A677.
DOI: 10.1016/j.jval.2017.08.1675

R. Schaefer, M. Schlander:
Is The National Institute for Health And Care Excellence In The United Kingdom More Innovation-Friendly Than The German Institute For Quality And Efficiency in Health Care In Germany?
Oral presentation at 14th HTAi Annual Meeting 2017, session on "Country-specific and regional HTA".
Rome, Italy. June 20, 2017.
International Journal of Technology Assessment in Health Care, 2017: 33(S1) 43-44.
DOI: 10.1017/S0266462317001672

M. Schlander, R. Schaefer, O. Schwarz:
An update on the economic value of a statistical life year in Europe.
Oral presentation at 14th HTAi Annual Meeting 2017, session on "Economic evaluation and decision making (B)".
Rome, Italy. June 20, 2017.
International Journal of Technology Assessment in Health Care, 2017: 33(S1) 44.
DOI: doi:10.1017/S0266462317001684

M. Schlander, O. Schwarz, R. Schaefer:
The monetary value of statistical life year: A systematic review.
Oral presentation at 14th HTAi Annual Meeting 2017, session on "Economic evaluation and decision making (B)".
Rome, Italy. June 19, 2017.
International Journal of Technology Assessment in Health Care, 2017: 33(S1) 192-193.
DOI: 10.1017/S0266462317003592

Non-refereed presentations (selection)

2023

M. Schlander:
An Introduction to HTA & Health Economics.
Presentation at the University of Heidelberg.
Heidelberg, Germany. January 26, 2023.

2022

M. Schlander:
Krebs und Armut: Pandemie als Brennglas für soziale und ökonomishce Ungleichheit.
Invited oral presentation at the 35th German Cancer Congress (DKK).
Berlin, Germany. November 13-16, 2022.

M. Schlander:
Risikoadaptierte Früherkennung & Prävention.
Invited oral presentation at the 35th German Cancer Congress (DKK).
Berlin, Germany. November 13-16, 2022.

M. Schlander:
Health Economics: its potential contribution to the success of a major biomedical research center.
Presentation at Summer School in Translational Cancer Research.
Albufeira, Portugal. October 20, 2022.

M. Schlander:
The Role and Potential Contribution of Health Economics to the Success of a Major Biomedical Research Cent
Presentation at Lecture Series "Science@DKFZ".
Heidelberg, Germany. September 26, 2022.

M. Schlander:
The cost of new drug development.
Online presentation at BPI (Bundesvergand der Pharazeutischen Industrie)-Ausschuss Klinische Forschung.
Berlin, Germany. September 13, 2022.

2021

M. Schlander:
The need for an adapted approach to value assessment of orphan medicines.
Presentation at Rare Conversations – European Rare Disease Ecosystem: A Collaborative Path Forward.
Online, November 9, 2021.

2019

C.-Y. Cheng, S. Calderazzo, M. Schlander:
Simulating the natural history of colorectal cancer using a variant of discrete event simulation: preliminary results before calibration.
Presentation at DKFZ, PhD Poster Presentation.
Heidelberg, Germany. November 22, 2019.
 
R. Schaefer, D. Hernández, M. Schlander:
Cancer-related health technology assessment (HTA) outcomes by European HTA agencies: a comparative analysis of G-BA, HAS and NICE.
Presentation at DKFZ, PhD Poster Presentation.
Heidelberg, Germany. November 22, 2019.
 
J. Ubels, K. Hernandez Villafuerte, M. Schlander:
The Limitations of Assessing the Value of Freedom in Economic Evaluation.
Presentation at DKFZ, PhD Poster Presentation.
Heidelberg, Germany. November 22, 2019.
 
M. Schlander:
What does value mean in rare disease?
Presentation at Innovation Forum.
Oxford, UK. April 1, 2019.
 
M. Schlander:
Training “Health Economics”
Presentation at Grünenthal Talent Programme by Frankfurt School.
Frankfurt, Germany. March 27, 2019.

2018

M. Schlander:
Exploring the health economics of cancer and cancer care: Advances, challenges, and current issues.
Guest Lecture. Lecture series: "Aktuelle Themen der Gesundheitsökonomik".
University of Mannheim, Faculty of Economics.
Mannheim, Germany. October 10, 2018.

M. Schlander:
Kostenintelligenz: Das Gesundheitssystem im Spannungsfeld zwischen einer alternden Gesellschaft und steigenden Kosten. [Cost intelligence: The healthcare system in the field of tension between an aging society and rising costs]
Guest Lecture. 7th Jahrestagung House of Pharma & Healthcare.
Frankfurt, Germany. September 11, 2018.

M. Schlander:
Measuring health-related quality of life.
Oral presentation at Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG).
Köln, Germany. July 9, 2018.

M. Schlander:
Sustainability: budgetary impact and cost drivers for rare and ultra-rare diseases.
Invited Presentation at International Workshop on "Health Systems Resilience for Rare Diseases". European Reference Network (ERN) on Rare Diseases.
Paris, France. June 27, 2018.

2017

D. Rees, S. Shah, M. Schlander, A. Wildi, J. Cain, A. Angelis:
The Evolving Approach to Drug Value Assessment in Global Markets.
Educational Symposium presented at ISPOR 20th Annual European Congress.
Glasgow, UK. November 5, 2017.
Program Booklet, Glasgow 2017, p. 11.

K. Loth, N. Bedlington, N. Hedberg, N. Moll, M. Schlander:
Have a voice in the pricing debate: medicines pricing simulation.
Invited lunch symposium presented at European Health Forum Gastein (EHFG).
Bad Hofgastein, Austria. October 5, 2017.

M. Schlander:
Examples of early access around the world: Germany.
Oral presentation at Symposium on "Early Access to Innovative Treatments" organized by the Turkish Health Economics and Policy Association (HEPA).
Istanbul, Turkey. December 8, 2017.

M. Schlander:
Societal willingness to pay methodologies for high-value medicines for rare diseases.
Oral presentation at International Symposium on "Accessibility to High-Value Medicines" organized by London School of Hygiene & Tropical Medicine.
London, UK. December 6, 2017.

M. Schlander:
HTA im deutschen Medizinproduktemarkt: Prinzipien, Prozesse, exemplarische Umsetzung. [Health Technology Assessment (HTA) for medical products – how to cope with the increasing regulatory burden?].
MedTechDialog „Navigating the Perfect Storm: Kosten-Nutzen-Bewertung / HTA für Medizinprodukte" (invited presentation); Mannheim Medical Technology Cluster.
Mannheim, Germany. March 23, 2017.

M. Schlander:
Common principles for value determination and assessment.
Invited panel contribution at "Second multi-stakeholder symposium on improving access to rare disease therapies", Eurordis.
Brussels, Belgium. February 23, 2017.

to top
powered by webEdition CMS